Roche Removes a Blemish: Drugmaker Drops Its One-Time Acne Blockbuster Accutane
This article was originally published in The Pink Sheet Daily
Executive Summary
Holding less than 5 percent of isotretinoin market and burdened with the costs of personal injury suits, Roche decides to discontinue its acne drug.